XML 60 R43.htm IDEA: XBRL DOCUMENT
v3.26.1

SHARE-BASED PAYMENTS (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Share-based payments [Abstract] |
Summary of share-based payment expense | The following table sets forth the total share-based payment expense for the years ended December 31, in relation to all directors and employees of the Company. Refer to Note 24—Related parties of these consolidated financial statements for specific disclosures on key management personnel remuneration:
| 2025 | 2024 | 2023
Equity-settled share-based payment expense | 26 |  | 18 |  | 18 |
Cash-settled share-based payment expense | 5 |  | 18 |  | 3 |
Total share-based compensation expense | 31 |  | 36 |  | 21 |
Summary of share-based payment liability | The following table sets forth the total share-based payment liability in relation to all directors and employees of the Company.
| 2025 | 2024
Current liability | 7 |  | 6 |
Non-current liability | 5 |  | 9 |
Total liability for share-based payments | 12 |  | 15 |
Summary of Roll-forward of shared-based payments | The following is the movement of shares granted during the year ended December 31, 2025 and 2024:
| 2025 | 2024
Market performance conditions | Awards* | Weighted Average Fair Value at grant date | Awards* | Weighted Average Fair Value at grant date
As of January 1, | 32,156,279 | $ | 0.80 |  | 28,967,451 | $ | 0.65 |
Granted | — |  | — |  | 18,485,474 | 0.80 |
Forfeited | (4,300,965) | 0.78 | (15,296,646) | 0.51 |
Vested and settled ** | — |  | — |  | — |  | — |
As of December 31, | 27,855,314 | $ | 0.81 |  | 32,156,279 | $ | 0.80 |
Of which: |  |  |  |
Vested, transfer in progress *** | (18,108,066) | $ | 0.64 |  | — | $ | — |
Unvested, as of December 31, | 9,747,248 | $ | 1.10 |  | — | $ | — |
| 2025 | 2024
Non-market performance conditions | Awards* | Weighted Average Fair Value at grant date | Awards* | Weighted Average Fair Value at grant date
As of January 1, | 16,856,239 | $ | 0.77 |  | 13,940,700 | $ | 0.65 |
Granted | 1,085,773 |  | 0.71 |  | 14,089,211 | 0.80 |
Forfeited | (3,148,142) | 0.76 |  | (1,964,551) | 0.61 |
Vested and settled ** | (5,269,492) | 0.58 |  | (9,209,121) | 0.66 |
As of December 31, | 9,524,378 | $ | 0.88 |  | 16,856,239 | $ | 0.77 |
Of which: |  |  |  |
Vested, transfer in progress *** | (6,123,957) | $ | 0.63 |  | (7,221,457) | $ | 0.55 |
Unvested, as of December 31, | 3,400,421 | $ | 1.33 |  | 9,634,782 | $ | 0.94 |
* To ensure data consistency, all awards were converted to VEON common share price equivalents. ** Vested and settled include all awards settled/transferred to the award holders in gross in the current year, whether granted and vested in current or previous periods. *** Vested, transfer in progress include all awards which are fully vested as at December 31, 2025 but in process of transfer to the award holders, whether granted and vested in current or previous periods. Note 24—Related parties of these consolidated financial statements for the Key Management Personnel, while further information for the share based portion of the STI compensation expense is disclosed below.
| 2025 | 2024
| Awards* | Weighted Average Fair Value at grant date | Awards* | Weighted Average Fair Value at grant date
As of January 1, | 5,771,196 | $ | 0.82 |  | 5,486,625 | $ | 0.72 |
Granted | 1,134,075 | 1.82 |  | 5,465,163 | 0.94 |
Forfeited | (45,394) | 1.29 |  | — | — |
Vested and settled ** | (4,243,998) | 0.83 |  | (5,180,592) | 0.84 |
As of December 31, | 2,615,879 | $ | 1.23 |  | 5,771,196 | $ | 0.82 |
Of which: |  |  |  |
Vested, transfer in progress *** | (1,632,725) | $ | 1.26 |  | (1,059,550) | $ | 0.95 |
Unvested, as of December 31, | 983,154 | $ | 1.18 |  | 4,711,646 | $ | 0.79 |
* To ensure data consistency, all awards were converted to VEON common share price equivalents. **Vested and settled include all awards settled/transferred to the award holders in gross in the current year, whether granted and vested in current or previous periods. *** Vested, transfer in progress include all awards which are fully vested as at December 31, 2025 but in process of transfer to the award holders, whether granted and vested in current or previous periods..
| 2025 | 2024
| Awards* | Weighted Average Fair Value | Awards* | Weighted Average Fair Value
As of January 1, | 19,864,641 | $ | 1.02 |  | 8,649,036 | $ | 0.78 |
Granted | 250,000 | 1.76 |  | 21,921,969 | 1.00 |
Forfeited | (224,087) | 0.95 |  | — | — |
Vested and settled ** | (3,890,572) | 0.95 |  | (10,706,364) | 0.79 |
As of December 31, | 15,999,982 | $ | 1.05 |  | 19,864,641 | $ | 1.02 |
Of which: |  |  |  |
Vested, transfer in progress *** | — | $ | — |  | (3,890,572) | $ | 0.95 |
Unvested, as of December 31, | 15,999,982 | $ | 1.05 |  | 15,974,069 | $ | 1.04 |
* To ensure data consistency, all awards were converted to VEON common share price equivalents. **Vested and settled include all awards settled/transferred to the award holders in gross in the current year, whether granted and vested in current or previous periods. *** Vested, transfer in progress include all awards which are fully vested as at December 31, 2025 but in process of transfer to the award holders, whether granted and vested in current or previous periods. The following is the movement of shares granted during the year ended December 31, 2025:
| 2025
Market performance conditions | Awards* | Weighted Average Fair Value at grant date
As of January 1, | — |  | $ | — |
Granted | 14,329,275 | $ | 0.74 |
Forfeited | — |  | $ | — |
Vested and settled ** | — |  | $ | — |
As of December 31, | 14,329,275 | $ | 0.74 |
| 2025
Non-market performance conditions | Awards* | Weighted Average Fair Value at grant date
As of January 1, | — | $ | — |
Granted | 1,176,400 | $ | 2.16 |
Forfeited | — | $ | — |
Vested and settled ** | — | $ | — |
As of December 31, | 1,176,400 | $ | 2.16 |
| 2025
Service conditions | Awards* | Weighted Average Fair Value at grant date
As of January 1, | — | $ | — |
Granted | 685,000 | $ | 1.60 |
Forfeited | — | $ | — |
Vested and settled ** | — | $ | — |
As of December 31, | 685,000 | $ | 1.60 |
* To ensure data consistency, all awards were converted to VEON common share price equivalents. **Vested and settled include all awards settled/transferred to the award holders in gross in the current year, whether granted and vested in current or previous periods
Summary of Fair value assumptions share-based payments | Since there are no grants awarded under the LTIP in 2025, the following table only sets forth the range of principal assumptions applied by VEON in determining the fair value of equity settled share based payment instruments with market performance conditions granted in 2024 and for liability settled awards with market performance conditions granted in previous years remeasured during the year ended December 31, 2025 and 2024:
Assumptions used in fair value models for equity-settled awards granted in 2024 and for the remeasurement of liability-classified market condition awards as of December 31, 2025 and 2024 | 2025 Range | 2024 Range
Annual risk-free rates of return and discount rates (%) | 3.36% | 2.42%— 4.33%
Long-term dividend yield (%) | —% | —%
Volatility of share price (%) | 55.18% | 31.35%—82.75%
Share price (p)* | $2.10 | $0.93— $1.60
* To ensure data consistency, all awards were converted to VEON common share price equivalents. The following table sets forth the range of principal assumptions applied by VEON in determining the fair value of equity settled share based payment instruments with market performance conditions and for liability-settled awards with market performance conditions remeasured during the year ended December 31, 2025:
Assumptions affecting inputs to fair value models for equity-settled awards granted in 2025 and for liability-settled awards for remeasurement as of December 31, 2025 of market condition awards | 2025 Range
Annual risk-free rates of return and discount rates (%) | 3.54%—4.05%
Long-term dividend yield (%) | — | %
Volatility of share price (%) | 43.09%—50.24%
Share price (p)* | $1.96—$2.32
* To ensure data consistency, all awards were converted to VEON common share price equivalents.

X
- Definition The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2025-01-01 -Paragraph 47 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2025-01-01 -Paragraph 45 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 31 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 31 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of Share-based Payment Expense + References No definition available. + Details
Name: | vip_ScheduleOfShareBasedPaymentExpenseTableTextBlock
Namespace Prefix: | vip_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of Share-based Payment Liability + References No definition available. + Details
Name: | vip_ScheduleOfShareBasedPaymentLiabilityTableTextBlock
Namespace Prefix: | vip_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share-based payments [Abstract] + References No definition available. + Details
Name: | vip_ShareBasedPaymentsAbstract
Namespace Prefix: | vip_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration